{"id":"recombinant-streptokinase","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Bleeding"},{"rate":"1-5","effect":"Allergic reaction"},{"rate":"5-15","effect":"Hypotension"},{"rate":"5-10","effect":"Arrhythmia"},{"rate":"1-5","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108147","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Streptokinase is a serine protease produced by Streptococcus bacteria that binds to plasminogen and converts it to its active form, plasmin. Plasmin then degrades fibrin, the main structural component of blood clots, leading to thrombolysis. This mechanism makes it effective for treating acute thrombotic events where rapid clot dissolution is needed.","oneSentence":"Recombinant streptokinase is a fibrinolytic enzyme that activates plasminogen to plasmin, dissolving blood clots by breaking down fibrin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:19.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction"},{"name":"Acute ischemic stroke"},{"name":"Pulmonary embolism"},{"name":"Deep vein thrombosis"}]},"trialDetails":[{"nctId":"NCT07374978","phase":"NA","title":"Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-07-01","conditions":"Pulmonary Embolism Subacute Massive, Thrombolytic Therapy","enrollment":100},{"nctId":"NCT01305226","phase":"PHASE3","title":"A Trial Using Double-Bolus THR-100 Versus Streptokinase","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2010-10","conditions":"Acute Myocardial Infarction","enrollment":120},{"nctId":"NCT00968929","phase":"PHASE4","title":"Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2006-06","conditions":"Pulmonary Embolism, Pulmonary Thromboembolism","enrollment":83}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Recombinant Streptokinase","genericName":"Recombinant Streptokinase","companyName":"Beijing Chao Yang Hospital","companyId":"beijing-chao-yang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant streptokinase is a fibrinolytic enzyme that activates plasminogen to plasmin, dissolving blood clots by breaking down fibrin. Used for Acute myocardial infarction, Acute ischemic stroke, Pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}